Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
4.660
+0.300 (6.88%)
At close: Oct 8, 2025, 4:00 PM EDT
4.687
+0.027 (0.57%)
After-hours: Oct 8, 2025, 7:07 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,750,500
Market Cap
9.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6 | 0 | - |
Dec 31, 2023 | 6 | -1 | -14.29% |
Dec 31, 2022 | 7 | 2 | 40.00% |
Dec 31, 2021 | 5 | 0 | - |
Aug 31, 2021 | 5 | 2 | 66.67% |
Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ARTL News
- 7 days ago - Artelo Biosciences Announces Closing of $2.0 Million Public Offering - GlobeNewsWire
- 8 days ago - Artelo Biosciences Announces Pricing of $2.0 Million Public Offering - GlobeNewsWire
- 9 days ago - Artelo Biosciences Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 9 days ago - Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces Closing of $3.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces Pricing of $3.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results - GlobeNewsWire
- 5 weeks ago - Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) - GlobeNewsWire